Puma Biotechnology, Inc.
10880 Wilshire Boulevard, Suite 2150
Los Angeles, CA 90024
July 28, 2022
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: | Tim Buchmiller |
Re: | Puma Biotechnology, Inc. |
Registration Statement on Form S-3 (Registration No. 333-266306)
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission (the “Commission”) of the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) of Puma Biotechnology, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on August 1, 2022, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Shayne Kennedy at (714) 755-8181 or, in his absence, Taylor Ashton at (714) 755-8208.
Thank you for your assistance in this matter.
Very truly yours,
Puma Biotechnology, Inc. | ||
| By: | /s/ Maximo F. Nougues | |
| Maximo F. Nougues | ||
| Chief Financial Officer | ||
CC: | Alan H. Auerbach, Puma Biotechnology, Inc. |
